Clinical Trial

Psoriatic Immune Response to Tildrakizumab

Name: Psoriatic Immune Response to Tildrakizumab — clinical trial record (NCT05390515)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.

Trial Details

NCT Number	NCT05390515
Lead Sponsor	University of California, San Francisco Collaborators: Sun Pharmaceutical Industries Limited
Conditions	Psoriasis Vulgaris
Enrollment	10 participants
Start Date	2022-09-01
Primary Completion	2028-09-01 (estimated)
Study Completion	2028-09-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-04